Five years later, Nito Biosciences is putting an end to its operation after the poor clinical outcomes of its flagship neurological program. The company is a Massachusetts-based biotech that has chosen to shut down after its initial drug candidate did not perform well in one of the midstage clinical trials, and this is the termination of the company’s efforts.
In 2020, 5 AM Ventures introduced Nido via its 4:59 Initiative, and it aimed to address the hard-to-treat neurological conditions. The company kept operating rather low profile until 2023, when it officially came out with a funding amount of 109 million dollars. It had a high-profile investor portfolio with such partners as Eli Lilly, as well as biotech-oriented venture capital firm Bioluminescence Ventures, among others. Nido then positioned itself as a firm with a foundation on the latest functional genomics to discover breakthrough treatment targets in neurology and inflammatory disease.
The most developed asset of the company was NIDO-361, which was in the development of Kennedy disease or spinal and bulbar muscular atrophy (SBMA). It is a rare hereditary neuromuscular disease, which usually shows up later in life and advances slowly throughout decades, resulting in gradual weakness and atrophy of muscles. SBMA is an X-linked disorder, and hence, it is more common among men, whereas women are also less affected by the disorder.
NIDO-361 is a small-molecule therapeutic meant to treat transcriptional dysregulation, and the objective is to repair normal cellular activity in the impacted patients. A global Phase 2 clinical trial was conducted on the drug in people with SBMA who were the participants of the trial. But the research did not give the company the amount of efficacy it had anticipated, which eventually led the leadership to make a hard call to close down operations.
According to a post on LinkedIn, the result was extremely difficult to the whole team to the extent that it was narrated by the CEO, Jeremy Springhorn, Ph.D. He pointed out that the disappointment was enhanced by the expectation that the program had given to patients living with SBMA and to their families, who now had little to offer them in terms of treatment. The company anticipates completely terminating its activities at the beginning of 2026 (Springhorn).
Nido spokesperson informed Fierce Biotech that the closure will only impact a few employees, but did not specify the exact date or the winding-down.
It was also revealed that when Nido first appeared in the public spotlight in 2023, a second, unannounced program focused on a new biological pathway was announced. It was thought that the program might have potential application in a variety of neurodegenerative and peripheral inflammatory diseases, but it never received as much high-profile coverage as NIDO-361.
At its heart, Nito Biosciences was constructed based on a human cell-based functional genomics discovery system, which could find new drug targets in complex disorders like amyotrophic lateral sclerosis and the frontotemporal disorders. Although the platform had a scientific ambition, the failure of its lead program ended up being overwhelming, and the work of the company came to an end.
The closure of Nido reflects the challenges facing small biotech firms in translating early-stage innovation into clinical success. Experts note that even with advanced genomics platforms, neurological disorders remain difficult targets due to their complexity and slow disease progression.
Investors and researchers also point out that Nido’s approach, while ambitious, underscores the financial risks inherent in high-cost, high-stakes biotech programs. Despite significant funding, including contributions from Eli Lilly, the inability to achieve meaningful efficacy in SBMA demonstrates the unpredictability of drug development in rare neurological diseases.
Going forward, the data from NIDO-361’s trials may still provide valuable insights for other researchers exploring transcriptional dysregulation in neuromuscular disorders. In this sense, while Nido as a company may cease operations, its scientific contributions could inform future therapeutic strategies for rare neurological diseases.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
